Our view is that a new local treatment mechanism could change how some cancers are managed over time.
Potential for a very high benefit–risk ratio and broad use
Our view is that combining image-guided delivery with a rapidly self-limiting local effect has the potential for a very high benefit–risk ratio. The approach is intended for accessible lesions of diverse extracranial solid tumors, including lesions in breast, head and neck, and cervical cancers.
Phase 1 study planAn unusual starting point: human data before the IND
Before IND submission, the project had accumulated historical observations from about 25 people. The records describe changes in local tumor tissue and symptoms as well as adverse events, and shaped the clinical development plan.
Human observationsParallel development for people and companion animals
The project has an uncommon companion-animal case series: 22 animals with spontaneous tumors, including 19 dogs and 3 cats. Veterinary recruitment, imaging and follow-up made these cases difficult to collect. We are pursuing human and veterinary drug development in parallel and see a new local mechanism as a way to widen the few options available in pet oncology.
Companion-animal programThe uncommon path of an inventor-led drug program
The program grew out of an individual inventor’s work on chlorine dioxide technology. Sponsors and collaborating research teams are now taking that work through formulation development, testing and formal clinical planning.
Technology and company background